Cargando…

Immune Thrombocytopenia Purpura Secondary to COVID-19

A 73-year-old female with past medical history of essential hypertension, hyperlipidemia, seasonal allergies, and chronic back pain presented to the hospital with complaints of headaches, fevers, fatigue, generalized body aches, shortness of breath, and diarrhea. Initial complete blood count was rem...

Descripción completa

Detalles Bibliográficos
Autores principales: Bennett, Joseph, Brown, Christopher, Rouse, Michael, Hoffmann, Marc, Ye, Zhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362597/
https://www.ncbi.nlm.nih.gov/pubmed/32676257
http://dx.doi.org/10.7759/cureus.9083
_version_ 1783559522655141888
author Bennett, Joseph
Brown, Christopher
Rouse, Michael
Hoffmann, Marc
Ye, Zhan
author_facet Bennett, Joseph
Brown, Christopher
Rouse, Michael
Hoffmann, Marc
Ye, Zhan
author_sort Bennett, Joseph
collection PubMed
description A 73-year-old female with past medical history of essential hypertension, hyperlipidemia, seasonal allergies, and chronic back pain presented to the hospital with complaints of headaches, fevers, fatigue, generalized body aches, shortness of breath, and diarrhea. Initial complete blood count was remarkable for leukopenia with an absolute lymph count of 0.60 K/µL and severe thrombocytopenia (platelet count < 3 K/µL). She was tested for COVID-19 via nasopharyngeal swab polymerase chain reaction (PCR) testing and found positive. Additional labs showed an elevated D-dimer, C-reactive protein, fibrinogen, and lactate dehydrogenase. Vitamin B12 and folate levels were obtained and found to be normal. Peripheral smear showed no schistocytes or additional hematologic abnormalities apart from thrombocytopenia. The patient was transfused one unit of platelets with no improvement in platelet count. Fibrinogen count was obtained and found in normal range at 458 mg/dL. Prothrombin time (PT), activated partial thromboplastin time (aPTT), and international normalized ratio (INR) were all found to be normal. Immune thrombocytopenia purpura (ITP) was suspected and intravenous immunoglobulin (IVIG) was administered at a dose of 1 g/kg/day for two doses. By day 4, the patient had marked response to treatment with platelet recovery to 105 K/µL and subsequently discharged by day 5 with complete resolution of symptoms and platelet count of 146 K/µL. Twenty-eight days after discharge, she presented to hematology clinic with platelet count of 8 K/µL. Repeat nasopharyngeal swab PCR COVID testing was negative and she was treated with IVIG and pulse dexamethasone with prompt response, confirming suspicion of underlying, undiagnosed ITP prior to COVID infection.
format Online
Article
Text
id pubmed-7362597
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-73625972020-07-15 Immune Thrombocytopenia Purpura Secondary to COVID-19 Bennett, Joseph Brown, Christopher Rouse, Michael Hoffmann, Marc Ye, Zhan Cureus Internal Medicine A 73-year-old female with past medical history of essential hypertension, hyperlipidemia, seasonal allergies, and chronic back pain presented to the hospital with complaints of headaches, fevers, fatigue, generalized body aches, shortness of breath, and diarrhea. Initial complete blood count was remarkable for leukopenia with an absolute lymph count of 0.60 K/µL and severe thrombocytopenia (platelet count < 3 K/µL). She was tested for COVID-19 via nasopharyngeal swab polymerase chain reaction (PCR) testing and found positive. Additional labs showed an elevated D-dimer, C-reactive protein, fibrinogen, and lactate dehydrogenase. Vitamin B12 and folate levels were obtained and found to be normal. Peripheral smear showed no schistocytes or additional hematologic abnormalities apart from thrombocytopenia. The patient was transfused one unit of platelets with no improvement in platelet count. Fibrinogen count was obtained and found in normal range at 458 mg/dL. Prothrombin time (PT), activated partial thromboplastin time (aPTT), and international normalized ratio (INR) were all found to be normal. Immune thrombocytopenia purpura (ITP) was suspected and intravenous immunoglobulin (IVIG) was administered at a dose of 1 g/kg/day for two doses. By day 4, the patient had marked response to treatment with platelet recovery to 105 K/µL and subsequently discharged by day 5 with complete resolution of symptoms and platelet count of 146 K/µL. Twenty-eight days after discharge, she presented to hematology clinic with platelet count of 8 K/µL. Repeat nasopharyngeal swab PCR COVID testing was negative and she was treated with IVIG and pulse dexamethasone with prompt response, confirming suspicion of underlying, undiagnosed ITP prior to COVID infection. Cureus 2020-07-09 /pmc/articles/PMC7362597/ /pubmed/32676257 http://dx.doi.org/10.7759/cureus.9083 Text en Copyright © 2020, Bennett et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Bennett, Joseph
Brown, Christopher
Rouse, Michael
Hoffmann, Marc
Ye, Zhan
Immune Thrombocytopenia Purpura Secondary to COVID-19
title Immune Thrombocytopenia Purpura Secondary to COVID-19
title_full Immune Thrombocytopenia Purpura Secondary to COVID-19
title_fullStr Immune Thrombocytopenia Purpura Secondary to COVID-19
title_full_unstemmed Immune Thrombocytopenia Purpura Secondary to COVID-19
title_short Immune Thrombocytopenia Purpura Secondary to COVID-19
title_sort immune thrombocytopenia purpura secondary to covid-19
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362597/
https://www.ncbi.nlm.nih.gov/pubmed/32676257
http://dx.doi.org/10.7759/cureus.9083
work_keys_str_mv AT bennettjoseph immunethrombocytopeniapurpurasecondarytocovid19
AT brownchristopher immunethrombocytopeniapurpurasecondarytocovid19
AT rousemichael immunethrombocytopeniapurpurasecondarytocovid19
AT hoffmannmarc immunethrombocytopeniapurpurasecondarytocovid19
AT yezhan immunethrombocytopeniapurpurasecondarytocovid19